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Calcium imagingStreptozotocin (STZ)-induced type 1 diabetes in rats leads to the development of peripheral diabetic neuropathy
(PDN) manifested as thermal hyperalgesia at early stages (4th week) followed by hypoalgesia after 8 weeks of
diabetes development. Here we found that 6–7 week STZ-diabetic rats developed either thermal hyper- (18%),
hypo- (25%) or normalgesic (57%) types of PDN. These developmentally similar diabetic rats were studied in
order to analyze mechanisms potentially underlying different thermal nociception. The proportion of IB4-
positive capsaicin-sensitive small DRG neurons, strongly involved in thermal nociception, was not altered
under different types of PDN implying differential changes at cellular and molecular level. We further focused
on properties of T-type calcium and TRPV1 channels, which are known to be involved in Ca2+ signaling and path-
ological nociception. Indeed, TRPV1-mediated signaling in these neurons was downregulated under hypo- and
normalgesia and upregulated under hyperalgesia. A complex interplay between diabetes-induced changes in
functional expression of Cav3.2 T-type calcium channels and depolarizing shift of their steady-state inactivation
resulted in upregulation of these channels under hyper- and normalgesia and their downregulation under
hypoalgesia. As a result, T-type window current was increased by several times under hyperalgesia partially un-
derlying the increased resting [Ca2+]i observed in the hyperalgesic rats. At the same time Cav3.2-dependent Ca2+
signaling was upregulated in all types of PDN. These ﬁndings indicate that alterations in functioning of Cav3.2
T-type and TRPV1 channels, speciﬁc for each type of PDN, may underlie the variety of pain syndromes induced
by type 1 diabetes.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Peripheral diabetic neuropathy (PDN) is one of the earliest, the most
frequent and troublesome complications of diabetes mellitus occurring
in about 66% of patients with type 1 diabetes [1]. As in humans, develop-
ment of PDN in rats is accompanied with various alterations in pain
sensation (hyper-, hypoalgesia, allodynia) or leaves pain sensationDRG, dorsal root ganglia; HMP,
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l rights reserved.unchanged (normalgesia) [2–5] and these alterationsmay be considered
as manifestation of different PDN types. Rats with streptozotocin (STZ)-
induced diabetes, a model of diabetes mellitus type 1, exhibit strong
thermal hyperalgesia at 4th week, progressing to hypoalgesia after
8 weeks of diabetes development [2]. At the same time, 6–7 week STZ-
diabetes represents a transition period of PDN, when the rats having
the same age and terms of diabetes are expected to reveal either
hyper-, or norm- or hypoalgesia [5] providing a model for PDN-type-
speciﬁc remodeling of cellular and molecular systems.
Impairment of Ca2+ homeostasis [6–9] and remodeling of voltage-
and ligand-gated ion channels [10–12] in nociceptive neurons have
been implicated in development of PDN. Among ion channels modulat-
ed in STZ-diabetes T-type calcium channels [13] and TRPV1 [14,15] are
both of exclusive importance for pathological nociception and directly
involved in intracellular calcium signaling. T-type calcium channels are
crucially involved in both acute [16–21] and neuropathic pain [22–25].
Moreover, in vivo selective block of T-type calcium channels effectively
reverses thermal hyperalgesia in STZ-diabetes [13]. On the other hand,
TRPV1 channels, “molecular integrators” of painful stimuli [26–30],
also play a key role in variations of thermal pain sensitivity (TPS) during
PDN development, that was directly demonstrated by unchanged TPS in
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IB4-positive small-sized DRG neurons [31], expressing both TRPV1 and
T-type channels [32,33], are of particular interest. These neurons,
being nonpeptidergic thermal C-type nociceptors (NTCN) [34], are
strongly involved in TPS [35] and play a key role in neuropathic pain
[36,37].
Here rats with thermal hyper-, hypo- and normalgesic PDN devel-
oped at the same age and duration of STZ-diabetes were used to de-
termine PDN type-speciﬁc remodeling of TRPV1 and T-type calcium
channels and their Ca2+ signaling in NTCN neurons.
2. Materials and methods
2.1. Experimental animals
MaleWistar ratswere housed in the animal facility of the Bogomoletz
Institute of Physiology (Kyiv, Ukraine), which was maintained at 22 °C,
55% relative humidity, with natural light/dark cycle. The animals
received a standard laboratory diet and tap water ad libitum. All experi-
mental protocols were approved by the Animal Care and Use Committee
of the Bogomoletz Institute of Physiology (Kyiv, Ukraine) andwere in ac-
cordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals. Every effort was made to minimize animal
suffering and the number of animals used.
2.2. Induction of experimental diabetes
We used a well establishedmodel of streptozotocin (STZ) injections
to induce diabetic neuropathy in young male Wistar rats (30–50 g,
21–23 days old) [9,38]. Experimental diabetes was induced in rats by
a single intraperitoneal injection of STZ solution (80 mg/kg, i.p.). STZ
was prepared in saline (0.9% NaCl adjusted to pH 4.3 with citric acid)
on ice; the solutionwas discarded if bubblingwas noted.We used intact
(naive) age-matched rats for most control in vitro experiments. Blood
glucose levels were checked on the 3rd day after the injection (to verify
diabetes onset) and just before electrophysiological experiments
(6–7 weeks after injections), using a blood glucometer (Accu-check Ac-
tive; Roche Diagnostics, Indianapolis, IN, USA). Rats with values of
>270 mg/dL (15 mM) were considered hyperglycemic and were in-
cluded in the respective experimental group.
2.3. Assessment of thermal nociception (behavioral experiments)
Nociceptive responses to thermal stimulation were measured using
Hargreaves' method [16,39]. A paw thermal stimulation system (Plan-
tar Test (Hargreaves's Apparatus), Ugo Basile, Italy) was used in these
experiments. Each animalwas placed in a plastic chamber of the system
to accommodate for 15 min. A radiant heat source mounted on a mov-
able holder beneath the glass ﬂoor was positioned to deliver a thermal
stimulus to the plantar side of the hind paw. When the animal with-
draws the paw, a photocell detects interruption of a light beam reﬂec-
tion and the automatic timer shuts off. This method has a precision of
±0.05 s for the measurement of paw withdrawal latency (PWL). To
prevent thermal injury, the light beam automatically discontinued at
20 s if the rat failed to withdraw its paw. PWL was obtained for each
tested rat as a mean of 10measurements with 5 min interval interleav-
ing left and right hind paws.
2.4. Acutely dissociated dorsal root ganglia neurons
We prepared dissociated dorsal root ganglia (DRG) cells and used
them within 6–8 h for whole-cell recordings as described previously
[40]. In brief, we dissected two L4 and two L5 DRGs from each animal,
cut each one into three to four pieces, and incubated the pieces in
Tyrode's solution containing 140 mM NaCl, 4 mM KCl, 2 mM MgCl2,
2 mM CaCl2, 10 mM glucose, and 10 mM HEPES, adjusted to pH 7.4with NaOH and supplemented with 1 mg/ml protease Type XIV
(Sigma) and 0.5 mg/ml collagenase Type I (Worthington Biochemical
Corporation) water bathed at 35 °C for 18–20 min. L4 and L5 ganglia
were chosen since they contain cell bodies of sensory neurons innervat-
ing peripheral receptive ﬁelds of the hind paws. Following incubation,
gangliawerewashed three times (Tyrode's solution, room temperature)
and dissociated into single cells in three cycles of trituration with glass
pipettes having progressively narrower tip diameters. For recordings,
the isolated neurons were plated onto an uncoated glass coverslip,
placed in a culture dish, and perfused with Tyrode's solution. All record-
ingswere obtained from isolatedDRG cells without visible processes. All
experiments were done at room temperature. We routinely observed
small, medium, and large sized neurons in the same preparation but,
in this study, focused only on cells with a soma diameter less than
30 μm (small DRG neurons) [41].
2.5. Fluorescent imaging
TILL Photonicswide-ﬁeld imaging system (TILL Photonics, Gräfelﬁng,
Germany) containing a monochromator Polychrome V and Imago CCD
camera was installed on an inverted microscope (IX71, Olympus) and
controlled by TILLvision software (TILL Photonics). An oil immersion ob-
jective (40× UV, NA 1.35; Olympus) was used for ﬂuorescent imaging.
Transmitted light images were captured using DIC of the same system.
2.6. Immunohistochemistry
Cells were incubated in Tyrode's solution supplemented with
10 μg/ml isolectin B4 (IB4) [42] conjugated to Alexa Fluor® 568 dye
(Invitrogen) in the dark for 10–12 min. Then a coverslip with the
cells was mounted in a 500-μl recording chamber perfused with a
room temperature (22 °C) Tyrode's solution at a gravity driven ﬂow
rate of 2 ml/min. Cells were visualized using a standard Rodamine Fil-
ter Set (Chroma Technology, USA). Fluorescent images were captured
under standardized settings from 15 to 20 randomly selected small
DRG cells on each dish before any electrophysiological recordings
during the ﬁrst 15 min of each experiment. Attribution of each cell to
one of three classes by ability of IB4-binding (strongly IB4-positive,
weakly IB4-positive and IB4-negative) and analysis of obtained distri-
bution were performed ofﬂine following Fang and collaborators [43].
The mean intensity of halo of IB4 staining around the neuronal plasma
membrane was determined for each neuron using image analysis
tools of TILLvision software (TILL Photonics). Then the relative intensity
was calculated separately for neurons of each coverslip. The 0 and 100%
intensity values for a particular coverslip were calculated by averaging
the halo intensity of the two least intensely (0%, a) and two most in-
tensely stained cell proﬁles (100%, b). For each tested neuron, its halo
intensity of (c) was used to determine its relative intensity (percentage
of maximum) as (100×(c−a)/(b−a))%. Neurons were judged as IB4
positive (IB4+) if their relative intensities exceeded 20%, otherwise
they were scored as negative. Then IB4+ neurons were classed as
strongly IB4+ if their intensity was≥40% and weakly IB4+ if their in-
tensity was in a range of 20–40%. Fractions of neurons in the respective
classes obtained for a single coverslip were then averaged for each ani-
mal group.
2.7. Fluorescent calcium imaging
To measure cytosolic Ca2+ concentration ([Ca2+]i), the intrapipette
solution was supplemented with 200 μM of the high-afﬁnity Ca2+ indi-
cator Fura-2. After 10 min of intracellular dialysis, Fura-2 ﬂuorescence
reached a steady-state level. Autoﬂuorescence of unloaded cells had sig-
nal strength of less than 5% of the ﬂuorescence of loaded cells. Fura-2
ﬂuorescence was recorded at 510±20 nmwavelength during alternat-
ing 340- and 380-nmexcitation, and the ratio of ﬂuorescence at 340 and
380 nm (R) was calculated on a pixel-by-pixel basis. The frame capture
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region of interest in the digital image (TILLvision software) and an addi-
tional backgroundareawas recorded in eachﬁeld for on-line subtraction
of background ﬂuorescence [44]. Fluorescent recordings of [Ca2+]i tran-
sients were performed simultaneously with electrophysiological re-
cordings of corresponding currents by means of synchronization of
PatchMaster and TILLvision software. [Ca2+]i was calculated for each
neuron from the ﬂuorescent ratio, R, averaged over the region of inter-
est corresponding to the neuron according to the equation [45]:
Ca2þ
h i
i
¼ K  R−Rmin
R−Rmax
; ð1Þ
The constants Rmin, Rmax and K determined by calibration were 0.29,
3.8 and 690 nM, correspondently.
The amplitude of [Ca2+]i transient was measured from a
prestimulated level to the peak. Neurons with a resting level of
[Ca2+]i>300 nM were excluded from statistics.
2.8. Electrophysiology
Electrophysiological recordings were performed using a standard
whole-cell technique. Electrodes were pulled from borosilicate glass
microcapillaries with a ﬁlament (Sutter Instrument, Novato, CA) and
had a resistance from 3 to 4 MΩ when ﬁlled with an internal solution.
The recordings were performed using an EPC-10⁄2 ampliﬁer controlled
by PatchMaster software (HEKA, Freiburg, Germany). FitMaster soft-
ware (HEKA, Freiburg, Germany) was used for an ofﬂine data analysis.
Currents were low-pass ﬁltered at 2–5 kHz. Series resistance (Rs) and
capacitance (Cm) valueswere taken directly from readings of the ampli-
ﬁer after electronic subtraction of the capacitive transients. A series re-
sistance was compensated to the maximum extent possible (usually
~60–80%).
Multiple independently controlled glass syringes served as reser-
voirs for a gravity-driven local perfusion system. All drugs were
prepared as stock solutions: capsaicin, 10 mM; L-cysteine and Ni2+,
100 mM. Drugs were freshly diluted to the appropriate concentrations
at the time of experiments. L-Cysteine and Ni2+ were prepared in H2O,
and capsaicin was prepared in DMSO. The maximum concentration of
DMSO in any one experiment was 0.02%; at that concentration, DMSO
had no effect on the calcium currents or membrane potential [17].
For voltage-clamp experiments, the external solution used to isolate
calcium currents contained the following (in mM): 2 CaCl2, 2 MgCl2,
158 tetraethylammonium (TEA)-Cl, 10 Glucose and 10 HEPES adjusted
to pH 7.4 with TEA-OH. The internal solution used for all voltage-clamp
recordings contained the following (in mM): 146 CsCl, 2 MgATP, 2
MgCl2, 0.5 GTP-Na, 5 2Na-Phosphocreatin and 10 HEPES, adjusted to
pH 7.3 with CsOH. The internal solution was always supplemented
with 200 μM Fura-2 serving also as a Ca2+ buffer.
All chemicals were obtained from Sigma (St. Louis, MO) unless
otherwise noted.
Following previous works [38,46,47] T-type calcium current (LVA
component) was isolated using a protocol (inset of Fig. 4A) that includ-
ed two double-pulse stimulations consisting of a preconditioning pulse
(to either−95 mV or−60 mV) for 3 s followed by a “command” pulse
to −45 mV for 250 ms, during which currents and corresponding
[Ca2+]i transients were simultaneously recorded. The stimulation with
the preconditioning pulse to−95 mV was used to elicit a total (a sum
of LVA and HVA components) current (Fig. 4A1, a black trace). In 10 s
(after [Ca2+]i recovery) the stimulation with the preconditioning
pulse to−60 mV was applied to inactivate the LVA component and to
elicit the HVA current only (Fig. 4A1, a gray trace). The T-type calcium
current (Fig. 4A2) was obtained by subtraction of the HVA current
from the total current. The same subtraction was also performed for
[Ca2+]i transients (Fig. 4A3). The command pulse was chosen to be to−45 mV to minimize the HVA component while keeping the LVA com-
ponent near its maximum.
Responses to capsaicin were recorded at the end of experimental
procedure by bath application of Tyrode's solution supplemented
with capsaicin (2 μM).
2.9. Analysis
Statistical comparisons were performed using unpaired Student's t
test, one-way ANOVA, and χ2 or Fisher's exact test. All quantitative
data are expressed as means of multiple experiments±SEM.
2.10. Analysis of electrophysiological data
The amplitude of T-type current was measured as a difference be-
tween the current peak value and a current value at the end of a
depolarizing command pulse in order to avoid a residual HVA current.
T-type current inactivation kinetics was estimated as a decay constant
of single exponential ﬁt of each recorded current. Activation kinetics
was estimated as a time-to-peak of each recorded current.
Voltage dependencies of activation and steady-state inactivation
were described with single Boltzmann distributions of the following
forms:
for activation:
G Vð Þ
Gmax
¼ 1
1þ exp − VV1=2k
  ð2Þ
for inactivation:
I Vð Þ
Imax
¼ 1
1þ exp V−V1=2k
  ð3Þ
where conductance (G(V)) was deﬁned as PCD /(V−Er) (PCD is a peak
current density deﬁned as Ipeak/Cm and (V−Er) is an electrodriving
force for a membrane potential (V) and reversal potential (Er)
obtained from interpolation of I(V) dependence); Gmax is the maximal
conductance and Imax is the maximal peak current amplitude; V1/2 is a
voltage at which half of the current is activated or inactivated, and k
represents the voltage dependence (slope) of the distribution. The
ﬁtted values for V1/2 and k are reported with 95% linear conﬁdence
limits.
The predicted peak current density of the T-type current evoked
by a depolarization step to −45 mV (PCD−45, Fig. 7) was calculated
for different holding membrane potentials (V) as a point-by-point
product of the steady-state inactivation (I(V)/ Imax) and the experi-
mental PCDs recorded for steps from −95 to −45 mV (that is
PCD−45(−95)) (Fig. 4C); the products were further divided by a de-
gree of channel availability at −95 mV (I(−95)/ Imax) taken from
Fig. 5Bb (0.77 in control, 0.92 in hypo-, 0.91 in hyper-, and 0.89 in
normalgesia):
PCD−45 Vð Þ ¼ PCD−45 −95ð Þ 
I Vð Þ.
Imax
I −95ð Þ
Imax
ð4Þ
The prediction for the window current densities (iwindow, deﬁned
as Iwindow/C) was calculated for different membrane potentials (V)
by point-by-point product of PCD−45 (Fig. 6A) and activation curves
(G(V)/Gmax)(Fig. 5Ab) divided by a degree of channel activation at
−45 mV (G(−45)/Gmax) (taken from Fig. 5Ab: 0.64 in control, 0.72
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ratio of driving forces at V and at −45 mV ((V−Er)/(−45−Er)):
iwindow Vð Þ¼ PCD−45 Vð Þ 
G Vð Þ
.
Gmax
G −45ð Þ
Gmax
 V−Er−45−Er
ð5Þ
We paid close attention to the ﬁdelity of voltage-clamp recordings.
Cellswere discarded from further quantitative analysis of current kinet-
ics if we noted signs of poor voltage control such as slow tail currents,
sudden increase in the amplitude of inward current with a depolarizing
step of 10 mV increments, and/or irregular shape of the inward current.
2.11. Estimation of window T-type current contribution to the resting
[Ca2+]i
The estimation is based on a fact, that in a resting state a Ca2+ inﬂux
due to the window current (Iwindow) should be compensated by Ca2+
extrusion current (Iextr), i.e. Iwindow= Iextr. The value of Iextrwas estimat-
ed based on an amplitude (A) and decay time constant (τtr) of [Ca2+]i
transient (Fig. 4D) induced by the T-type current (Fig. 4B) having PCD,
iT, and a decay time constant, τi. To simplify calculations of charge (Q)
introduced into a neuron the T-type current was considered as
mono-exponential, and consequentlyQ= iT×C×τI, where C is a neuron
capacitance. We considered that for small changes of [Ca2+]i, from the
resting level induced by T-type current the Ca2+ extrusion is propor-
tional to changes in [Ca2+]i: Iextr=k1×Δ[Ca2+]i, where k1 is a constant
and Δ[Ca2+]i=[Ca2+]i−[Ca2+]i, resting. For small [Ca2+]i transients we
also suggested a proportionality between the amplitude of [Ca2+]i tran-
sient and the charge introduced by the T-type current: A=k2×Q, where
k2 is the other constant. From the previous equations k2 can be
expressed as k2=A/Q=A/(iT×C×τi). Next we have assumed that
rate of [Ca2+]i recovery is proportional to a rate of Ca2+ extrusion rep-
resented by Iextr with the same constant k2: dΔ[Ca2+]i/dt=−k2× Iextr.
After substitution of Iextr for k1×Δ[Ca2+]i we obtain: dΔ[Ca2+]i /
dt=−k2×k1×Δ[Ca2+]i, that is an equation for exponentially decaying
[Ca2+]i transient with a decay time constant of 1/(k2×k1) deﬁned
above as τtr. Thus, k1 can now be calculated as: k1=k2/τtr= iT×C×τi /
(A×τtr). Substituting k1 into the equation Iextr=k1×Δ[Ca2+]i and hav-
ing in mind that Iwindow= Iextr the contribution of the window current
to the resting [Ca2+]i may be estimated as Δ[Ca2+]i= Iwindow/k1:
Δ Ca2þ
h i
i
¼ A τtr
τi
 iwindow
iT
ð6Þ
where iwindow= Iwindow/C is the T-type window current density.
3. Results
3.1. TPS variation in the transition period of PDN
Within three days after the injection of STZ, most (70%) rats devel-
oped hyperglycemia (mean glucose concentration 29±2 mM) and
were considered as diabetic. At the same time, saline-injected animals
maintained a normal blood glucose level (4.1±0.2 mM) and did not
alter a thermal nociception threshold (n=10, p>0.9). In order to test
existence and direction of changes in thermal nociception for rats
with 6–7 weeks of STZ-induced diabetes (n=60) their pawwithdraw-
al latency (PWL), as a measure of TPS [16,39], was compared to age
matched control (n=90; Fig. 1A). PWL distributions for both animal
groups were Gaussian (Lilliefors normality test, p>0.05). There was
no signiﬁcant difference between means of the distributions (Fig. 1B):
corresponding values were 12.2±0.2 s in control and 13.0±0.5 s
under the diabetes. On the other hand a standard deviation of PWL dis-
tribution was signiﬁcantly greater under diabetes (4.2 s) as compared
to control (1.6 s) (p=8·10−15, F-test, F=0.16, Fcrit=0.68, Fig. 1C).Thus, PWL distribution under diabetic conditions had no shift but it
was signiﬁcantly wider than in control.
95% conﬁdence interval of PWL distribution for control rats was
8.9÷15.5 s. Based on this result, the diabetic rats were divided into
three groups (Fig. 1A): hyperalgesic (PWLb8.9 s, signiﬁcantly exag-
gerated response), hypoalgesic (PWL>15.5 s, signiﬁcantly attenuat-
ed response) and normalgesic (unchanged response, PWL within
8.9÷15.5 s). Hyper-, hypo- and normalgesic rats consisted 18% (11
of 60), 25% (15 of 60) and 57% (34 of 60) of diabetic animals, respec-
tively (Fig. 1D). The averaged PWLs for hyper-, hypo- and normalgesic
groups were 7.7±0.2 s, 18.7±0.5 s, and 13.2±0.5 s, correspondingly
(Fig. 1E). A blood glucose level of diabetic animals was signiﬁcantly dif-
ferent from that of control rats; at the same time no signiﬁcant differ-
ences in the blood glucose level and body weight were observed
between experimental rats of different diabetic groups (Table 1).
Thus, hyper-, norm- and hypoalgesic animals are simultaneously
present within the population of rats of the same age and terms of
STZ-induced diabetes. This was considered asmanifestation of different
types of PDN. 6–7 week STZ diabetic rats with hyper-, hypo- and
normalgesic types of PDNwere further used to analyzemechanisms un-
derlying alterations of thermal nociception induced by type 1 diabetes.
3.2. Development of PDN does not affect the proportion of nonpeptidergic
C-type nociceptors
Diabetes development may potentially result in cell death [48].
Moreover, a differential loss of peptidergic and nonpeptidergic primary
nociceptors correlates with changes in TPS [49]. Therefore, we checked
whether different types of PDN were associated with changes in a pro-
portion of nonpeptidergic versus peptidergic C-type nociceptors.
Using isolectin B4 (IB4) [50] for in vitro labeling of nonpeptidergic neu-
rons [34], small DRGneurons (n=608), considered as C-type nociceptors
[51], were divided into three classes based on the intensity of IB4 binding
[43]: strongly IB4-positive,weakly IB4-positive and IB4-negative. Fractions
of these neuronal classes were unchanged in all PDN groups compared to
control (p>0.05, χ2-test; Fig. 2). The IB4-positive small DRG neurons,
considered as nonpeptidergic polymodal C-type nociceptors [34,43],
were the most abundant and constituted 73±6%, 76±7%, 78±8%, and
76±7%of control, hyper-, hypo- andnormalgesic groups, corresponding-
ly. Known as being involved in thermal nociception [35] and neuropathic
pain [36], this neuronal class became the focus of further experiments.
Thus, there was no signiﬁcant redistribution between C-type
nociceptors of IB4-positive, weakly IB4-positive and IB4-negative neuro-
nal classes under different types of PDN. Therefore, differences in TPS
are unlikely to have developed due to speciﬁc changes in the proportion
of nonpeptidergic versus peptidergic C-type primary nociceptors, rath-
er implying impairments of molecular signaling systems in these
neurons.
3.3. Signaling by TRPV1 channels is oppositely modiﬁed under hyperalgesic
versus hypoalgesic PDN
TRPV1 channels are involved in TPS [26,52] and, therefore,
changes in their functioning in the primary nociceptors may poten-
tially result in TPS abnormalities observed in rats with PDN. Thus,
we studied TRPV1 signaling under different types of PDN. For that
IB4-positive small-size DRG neurons were held in a voltage-clamp
mode at −60 mV and challenged with TRPV1 channels agonist, cap-
saicin. Most tested neurons (>85%) responded to capsaicin applica-
tion (2 μM, 15 s) with an inward current (Fig. 3A) and rise in
[Ca2+]i (Fig. 3C). These capsaicin-sensitive IB4-possitive small-size
DRG neurons were considered as NTCN neurons and were the focus
of all further experiments in this work.
No statistically signiﬁcant difference between the animal groups
was observed (p>0.05, χ2-test) in a fraction of NTCN neurons among
IB4-positive small-size DRG neurons. However, signiﬁcant PDN type-
Fig. 1. Different types of TPS are expressed in ratswith 6–7 weeks of STZ-induceddiabetes. (A)Normalizeddistribution of PWLs for control (n=90) and agematcheddiabetic (n=60) rats. The
bin width is 1.6 s. The diabetic rats were divided into three groups: normalgesic (Dn) having PWL in a range of 8.9÷15.5 s (corresponding to 95% conﬁdential interval for control rats),
hyperalgesic (D+)with PWL less than 8.9 s, andhypoalgesic (D−)with PWLexceeding 15.5 s. (B,C)Means (B) of PWLdistributions for control anddiabetic ratswerenot signiﬁcantly different,
(Student's t-test p>0.05) while their standard deviations (C) differed signiﬁcantly (***— Fisher's F-test pb0.001 vs control). (D) Fractions of hyper-, hypo- and normalgesic rats within the di-
abetic group. (E) PWLs of control, hyper-, hypo- and normalgesic rats.
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were found in these neurons. A peak current density (PCD) of
capsaicin-induced responses under hyperalgesic PDN was increased
by 45±11% as compared to control (201±16 pА/pF, n=15 under
hyperalgesia vs. 139±12 pА/pF, n=41 in control; pb0.05) (Fig. 3B).
On the contrary, in neurons of hypo- and normalgesic rats PCD wasTable 1
Blood glucose level and body weight of experimental rats.
Control Diabetica
Hyperalgesic Normalgesic Hypoalgesic
Blood glucose level, mM 4.2±0.2b 25±4 31±2 28±1
Body weightc, g 158±6 148±17 119±20 130±24
n 20 7 6 6
a There was no signiﬁcant differences between hyper-, hypo- and normalgesic diabetic
rats (p>0.1, ANOVA one-way test).
b t-test: pb0.001 for control vs each diabetic group.
c There was no signiﬁcant differences between hyper-, hypo- and normalgesic diabetic
and control rats (p>0.1, ANOVA one-way test).signiﬁcantly decreased as compared to control by 43±15% and 48±
12%, correspondingly (79±21 pА/pF, n=14 under hypoalgesia and
73±16 pА/pF, n=15 under normalgesia; pb0.05). Similarly, ampli-
tudes of capsaicin-induced [Ca2+]i transients were signiﬁcantly in-
creased (by 112±11%, n=15, pb0.001) under hyperalgesic PDN and
decreased under hypoalgesic (by 67±8%; n=14, pb0.001) and
normalgesic (by 67±7%, n=15, pb0.001) PDN as compared to control
(Fig. 3D).
A ratio of amplitudes of capsaicin-induced [Ca2+]i transient to
PCD reﬂects a degree of involvement of intracellular Ca2+ regulating
systems in the neuronal Ca2+ response to the same amount of Ca2+
entry. As compared to control this ratio was increased by 43±3%
(n=15, pb0.01) under hyperalgesic PDN and decreased under
hypoalgesic (by 55±8%, n=14, pb0.01) and normalgesic (by 38±
10%, n=15, pb0.05) PDN (Fig. 3F) implicating different impairments
of intracellular Ca2+-regulating systems under hyperalgesic versus
normalgesic and hypoalgesic PDN.
These results indicate that in NTCNneurons TRPV1-mediated signal-
ing is signiﬁcantly altered under PDN conditions. Moreover, these
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Fig. 2. Proportion between IB4-positive and IB4-negative small DRG neurons was not altered in rats with 6–7 weeks of STZ-induced diabetes. Bars represent fractions of strongly
IB4-positive (IB4+), weakly IB4+ and IB4-negative (IB4-) small DRG neurons in a control (C) (n=189 stained neurons), hyper- (D+) (n=147), hypo- (D−) (n=137) and
normalgesic (Dn) (n=140) groups. Fractions of strongly IB4+, weakly IB4+ and IB4− neurons were not signiﬁcantly different between 4 studied groups (p>0.05, χ2-test).
An inset shows a transmitted light (DIC optics) (top) and ﬂuorescent (bottom) images of the same strongly IB4+ small DRG neuron. Note an intensive ﬂuorescent ring associated
with the neuronal plasma membrane. Scale bar, 20 μM.
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PDN implying TRPV1 channels as a molecular system responsible for
differences in TPS. A signiﬁcant correlation between capsaicin re-
sponses and TPS (Fig. 3E) also corroborates this idea. However, the
same responses to capsaicin observed in normalgesic and hypoalgesic
PDN suggest an involvement of other molecular systems in the TPS
alterations.3.4. PDN-type-speciﬁc alterations of T-type calcium channel signaling in
NTCN neurons
Recent studies demonstrate that T-type calciumchannels [47,53] are
key mediators of nociceptive signaling by primary sensory neurons in
acute and neuropathic pain [16–21], including TPS in the hyperalgesic
PDN [13,38,54]. Therefore, we further examined T-channel-mediated
signaling in NTCN neurons under different types of PDN.
T-type currents (Fig. 4B,C) and corresponding [Ca2+]i transients
(Fig. 4D,E) isolated at −45 mV after a preconditioning at −95 mV
(Fig. 4A) were substantially altered in NTCN neurons under PDN con-
ditions as compared to control. T-type PCD (T-PCD) (Fig. 4C) was in-
creased by 38±8% under hyperalgesic PDN compared (5.0±0.4 pА/
pF, n=15) to control (3.6±0.3 pА/pF, n=41; pb0.05). On the con-
trary, T-PCD was decreased by 26±8% under hypoalgesic PDN
(2.7±0.3 pА/pF, n=14; pb0.05) and by 26±9% under normalgesic
PDN (2.6±0.2 pА/pF, n=15; pb0.01) compared to control. At the
same time inactivation kinetics of T-type current was not signiﬁcantly
different between control (26±2 ms), hyper- (27±4 ms), hypo-
(27±3 ms) and normalgesic (23±2 ms) groups (ANOVA, p>0.05).
Amplitudes of corresponding [Ca2+]i transients were signiﬁcantly
increased in all PDN groups compared to control (n=6) (Fig. 4D,E):
by 66±24% under hyperalgesia (n=6, pb0.05), by 55±18% under
hypoalgesia (n=5, pb0.05) and by 88±18% under normalgesia
(n=5, pb0.05). At the same time, a ratio of amplitude of [Ca2+]i
transient to T-PCD was signiﬁcantly increased only under hypoalgesic
(by 261±15%, n=5, pb0.01) and normalgesic (by 290±62%, n=5,
pb0.01) PDN, whereas under hyperalgesic PDN changes were not sig-
niﬁcant (52±32% n=6, p>0.5, Fig. 4F) compared to control (n=6).
The increase of the ratio implies that intracellular Ca2+ response to
the same amount of Ca2+ entry was speciﬁcally enhanced under
hypo- and normalgesia corroborating speciﬁc disruptions of intracel-
lular Ca2+-regulating systems of NTCN neurons under different types
of PDN.
Thus, we have found that T-channel-mediated signaling is sub-
stantially modiﬁed in NTCN neurons under PDN condition. Moreover,
observed changes are oppositely directed under hyperalgesic versus
normalgesic and hypoalgesic PDN.3.5. Cav3.2 (α1H) isoform of T-type channels is mainly expressed in
NTCN neurons under control and diabetic conditions
Cav3.2 isoform of T-type channels is most abundantly expressed in
DRG neurons [55]. To study functional contribution of Cav3.2 T-type
channels to T-type current in NTCN neurons under control and PDN
conditions we examined pharmacological properties of T-type current
using such Cav3.2-speciﬁc pharmacological tools as T-type channel
blockers, Ni2+ and amiloride, at low micromolar concentrations [56]
as well as an endogenous T-type channel agonist, L-cysteine [57].
T-type currentwas signiﬁcantly and reversibly blocked by bothNi2+
(50 μM) and amiloride (500 μM) in NTCN neurons of all experimental
groups. Ni2+ blocked 77±6% of T-PCD in the control (n=6), 79±5%
in the hyperalgesic (n=5), 75±7% in the hypoalgesic (n=5) and
82±5% in the normalgesic (n=5) animal groups. Amiloride blocked
84±4% of T-PCD in the control (n=7), 86±3% in the hyperalgesic
(n=5), 82±3% in the hypoalgesic (n=5), and 83±4% in the
normalgesic (n=5) groups. L-Cysteine (100 μM) signiﬁcantly and re-
versibly enhanced T-type currents in neurons of control rats as well as
in neurons of PDN animals. L-Cysteine increased the T-PCD by 63±
11% in the control (n=7), by 53±9% in the hypoalgesic (n=6), by
58±9% (n=6) in the hyperalgesic and 56±8% in the normalgesic
(n=5) groups. The effects of Ni2+, amiloride and L-cysteine were sta-
tistically signiﬁcant in all groups (pb0.001), but therewasno signiﬁcant
difference in the effect between the groups for each pharmacological
tool (ANOVA, p>0.05).
Taken together these ﬁndings demonstrate the same high contribu-
tion (>90%) of Cav3.2 T-type channels to the total T-type current in
NTCN neurons of control and PDN rats with no detectable alteration in
the proportion of Cav3.2 isoform in the total pool of T-type channels
during the transition period of PDN.
3.6. PDN alters biophysical properties of T-type channels in NTCN neurons
Changes in voltage-dependent activation and steady-state inacti-
vation (SSI) of T-type channels substantially inﬂuence the neuronal
excitability [58]. Therefore, we studied these biophysical properties
of T-type channels in NTCN neurons under different types of PDN.
The voltage-dependence of T-type channel activation, assessed via
a conventional double-pulse protocol (Fig. 5Aa), revealed no signiﬁ-
cant difference between midpoints (V1/2) as well as slope factors (k)
of the activation curves in control (V1/2=−48±1 mV, k=5.9±
0.8 mV, n=19), hyperalgesic (V1/2=−49±2 mV, k=5.2±0.3 mV,
n=9), hypoalgesic (V1/2=−50±1 mV, k=5±1 mV, n=8) and
normalgesic (V1/2=−50±1 mV, k=5.8±0.7 mV, n=13) types of
PDN (Fig. 5Ab; ANOVA, p>0.05). No signiﬁcant differences between
the control and PDN groups (ANOVA, p>0.05) were also observed
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Fig. 3. TRPV1 channels were downregulated under hypo- and normalgesia, while hyperalgesia was associated with their upregulation. (A) Representative traces of currents induced by acti-
vation of TRPV1 channelswith capsaicin (2 μM) inNTCNneurons of control and diabetic ratswith hyper-, hypo- and normalgesic types of PDN. (B) PCD of TRPV1 channels in theNTCNneurons
of PDN rats were signiﬁcantly different from control (*— pb0.05, **— pb0.01) and oppositely changed in hyper- versus hypo- and normalgesic rats. (C) Representative traces of [Ca2+]i tran-
sients corresponding to the currents shown in a. Baselines of traces were aligned to emphasize differences in amplitudes. (D) Normalized amplitudes of [Ca2+]i transients were signiﬁcantly
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a range of potentials from−65 mV to−30 mV (Fig. 5Ac). Thus, acti-
vation properties of T-type channels seem to be not affected under
PDN conditions.
The voltage-dependence of SSI (Fig. 5Bb) was obtained from T-PCDs
recorded at−40 mV in another conventional double-pulse protocol in-
volving the application of a series of preconditioning pulses (Fig. 5Ba).
We found about 7 mV depolarizing shift in the midpoint (V1/2) of SSI
curve in all PDN groups compared to control (Fig. 5Bc): corresponding
values of V1/2 were−89±2 mV in control cells (n=19),−81±2 mV
under hyperalgesia (n=9; pb0.01), −82±2 mV under hypoalgesia
(n=8; pb0.01) and −83±1 mV under normalgesia (n=13;
pb0.01). The slope factor of the SSI curve was not signiﬁcantly affectedunder PDN as compared to the control (5.4±0.2 mV): corresponding
values were 6.0±0.2 mV under hyperalgesia, 5.4±0.4 mV under
hypoalgesia and 6.0±0.3 mV under normalgesia (ANOVA, p>0.05).
Thus, in contrast to unchanged activation properties, inactivation of
T-type channels is signiﬁcantly affected in a similar way for different
types of PDN.
3.7. Speciﬁc upregulation of T-type channels under hyperalgesia and
normalgesia
Diabetes-induced changes in T-PCD described in Section 4 (Fig. 4C)
were found using a holding membrane potential (HMP) of −95 mV.
Due to a diabetes-induced shift in SSI (Fig. 5Bb) a degree of the T-PCD
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Fig. 4. Each PDN type is associatedwith speciﬁc changes in T-type channel signaling. (A) Electrophysiological isolation of T-type currents (1, 2) and corresponding [Ca2+]i transients (3).
The T-type current (A2)was obtained by a digital subtraction of high-voltage activated current (HVA, evoked from holding potential of−60 mV) from the total voltage activated calcium
current (A1) evoked after a 3 s preconditioning at a potential of−95 mV. Both currents were evoked by a depolarizing step to−45 mV (see an inset). The same subtraction procedure
was performed for the respective [Ca2+]i transients (A3). (B) Representative traces of T-type currents (after subtraction procedure) in the NTCN neurons of control, hyper-, hypo- and
normalgesic rats. (C) Pooled results of peak current densities of T-type channels, T-PCD, in the NTCN neurons of four studied groups. (D) Representative traces of [Ca2+]i transients
(after subtraction procedure) corresponding to currents shown in a panel (B). (E) Pooled results of normalized amplitudes of [Ca2+]i transients induced by activation of T-type channels.
(F) Pooled normalized ratios of amplitudes of [Ca2+]i transients to the respective PCD. *— pb0.05 and **— pb0.01 versus control; ##— pb0.01 for hypo- and normalgesic groups versus
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same potential of −45 mV (T-PCD−45) under conditions of different
HMP in NTCN neurons of hyper-, hypo- and normalgesic animals versus
control ones (see Eq. (4) in Materials and methods). The obtained de-
pendencies of T-PCD−45 onHMP clearly show speciﬁc and complex pat-
tern of changes observed under each type of PDN (Fig. 6A).
To visualize the relative changes in T-PCD−45 their dependencies for
each PDN typewere normalized point by point to corresponding control
values (Fig. 6B,C). Since activation properties of T-type channels were
almost the same for all experimental groups (Fig. 5Ab) such normalized
T-PCD were considered as dependent only upon HMP.
Firstwe looked atHMP≤−100 mV,where T-type channelswere al-
most fully recovered from inactivation. We found that T-PCD under
hyperalgesia was not signiﬁcantly different from control, while it wasalmost twice lower compared to control under hypo- and normalgesia
(Fig. 6C).
For HMP≥−90 mV T-PCD was signiﬁcantly increased under
hyperalgesia compared to control, suggesting functional upregulation
of T-type channels. At the same time, under hypoalgesia T-PCD was
not signiﬁcantly different from control (Fig. 6B), indicating the absence
of T-type channel upregulation.
In case of normalgesia T-PCD values were very similar to those
under hypoalgesia for HMP≤−75 mV. However, under normalgesia
in contrast to hypoalgesia, T-PCD values were signiﬁcantly increased
compared to control for HMP≥−70 mV (Fig. 6B), suggesting function-
al upregulation of T-type channels but less pronounced than in
hyperalgesia. It is also interesting to note that there was a large (almost
twofold) and signiﬁcant difference of T-PCD in a case of hyperalgesia
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rats. (Aa) Representative series of current traces demonstrates voltage-dependent activation of the T-type current. The currents were evoked by test pulses to−70 through−30 mV in 5 mV
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1/(1+exp(−(V−V1/2)/k)) (see Materials and methods for details). Note that the average ﬁts for control and all PDN groups almost overlap. (Ac) Pooled results of time to peak, TTP, plotted
against test potentials for the NTCN neurons of control and PDN rats. (B) T-type channel availabilitywas increased in PDN rats due to a shift of steady-state inactivation, SSI. (Ba) Representative
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644 E.V. Khomula et al. / Biochimica et Biophysica Acta 1832 (2013) 636–649versus hypoalgesia within the whole tested range of HMPs (Fig. 6D). At
the same time the difference in T-PCD between hyper- and normalgesia
became insigniﬁcant for HMP≥−70 mV (Fig. 6D).
Thus, T-type channels seem to be signiﬁcantly upregulated near
the resting membrane potential speciﬁcally in case of hyper- and
normalgesic PDN.
3.8. PDN affects T-type window current and resting [Ca2+]i in NTCN
neurons
An important functional consequence of the depolarizing shift of SSI
under PDNwas a larger overlap area between activation and inactivation
curves that may result in enhancement of a window Ca2+ current via
T-type channels [59]. To test this hypothesis, the window current wascalculated at different membrane potentials for control, hyper-, hypo-
and normalgesic groups (see Eq. (5) in Materials andmethods). The cal-
culations revealed a tendency to increase of T-type window under PDN
conditions compared to control, although signiﬁcance was reached
only under hyperalgesic (at HMP≥−60 mV) and normalgesic (at
HMP≥−55 mV). A sixfold increase was observed under hyperalgesia
near the resting membrane potential (at −60 mV) (Fig. 7A). As the
T-type window current may contribute to the resting level of [Ca2+]i
[60–62] we compared a resting [Ca2+]i in NTCN neurons clamped at
−60 mV between all experimental groups of animals (Fig. 7B). We
found that the resting [Ca2+]i was signiﬁcantly increased under
hyperalgesia (230±20 nM, n=9, pb0.001) and unchanged under
normalgesia (73±9 nM, n=7, p>0.95) compared to control (72±
11 nM, n=41). At the same time the resting [Ca2+]i was slightly
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645E.V. Khomula et al. / Biochimica et Biophysica Acta 1832 (2013) 636–649increased in the case of hypoalgesia (120±20 nM, n=13, pb0.05) in
spite of unchanged T-typewindow current, possibly due to impairments
of Ca2+ clearance from the cytosol [63,64]. Thus, the hyperalgesic PDN is
associated with the drastic increase of both the resting [Ca2+]i and
T-type window current in NTCN neurons.-35
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demonstrated that differences in TPS between hyper-, hypo- and
normalgesic diabetic rats are likely due to differential changes in func-
tioning of TRPV1 and T-type calcium channels within the existing pool
of NTCNneurons rather than due to elimination of this speciﬁc neuronal
class or redistribution between nonpeptidergic and peptidergic primary
nociceptors. Our results provide a better understanding of potential
molecularmechanisms involved in expression of different types of PDN.
4.1. Speciﬁc remodeling of TRPV1 channels was associated with different
types of PDN
TRPV1 channels were reciprocally dysregulated under hyper- and
hypoalgesia in the transition period of PDN development in STZ-diabetic
rats of the same age and duration of diabetes (Fig. 3A,B). Moreover, a sig-
niﬁcant correlation was found between PWL and TRPV1-mediated PCD
(Fig. 3E). In addition, TRPV1-mediated currents and [Ca2+] transients
were correspondently threefold and sixfold higher in hyperalgesia versus
both hypoalgesia and normalgesia. Together these ﬁndings corroborate
an important role of TRPV1 channels in expression of hyperalgesia and
hypoalgesia in a transition period of PDN development. Our results are
in agreement with previous reports about association between changes
in TRPV1 expression and direction of abnormalities in TPS shown for an-
imals of different ages and durations of STZ-diabetes (2–4th and 8th
weeks) [14,15].
[Ca2+] transients evoked by TRPV1 activationwere also reciprocally
altered in hyper- and hypoalgesia (Fig. 3C,D). However, the signiﬁcant
changes in a transient-to-current ratio (Fig. 3F) indicate that the differ-
ences in [Ca2+] transients are not proportional to the corresponding
changes in PCD under hyper- and hypoalgesic PDN. This likely reﬂects
impairments of intracellular calcium-regulating and calcium-buffering
systems observed previously [8,9,63,64].
Noteworthily, the restoration of thermal pain sensitivity in
normalgesic animals does not indicate recovery from PDN, since
TRPV1 and T-type channels and their Ca2+ signaling are still signiﬁ-
cantly impaired. Hence, post-STZ normalgesia may be truly consid-
ered as a separate type of PDN.
It is interesting to note that TRPV1 signaling under normalgesia is
downregulated to the same extent as under hypoalgesia. We suggest
that different remodeling of Cav3.2 T-type channels under normalgesic
and hyperalgesic PDN (Fig. 7B) underlies the differences in TPS between
these PDN types.
4.2. PDN-type-speciﬁc remodeling of Cav3.2 T-type channels
Kinetics of inactivation (Fig. 4), time- and voltage-dependence of
activation (Fig. 5) and pharmacological properties of T-type currents
(Section 3.5) in the NTCN neurons did not differ between control,
hyper-, hypo- and normalgesic animals. These ﬁndings indicate the
same high contribution (>90%) of Cav3.2 isoform to the total T-type
current in control and during the transition period of PDN. This con-
clusion is consistent with previous ﬁndings reporting that Cav3.2 is
the most abundant isoform of T-type channels in DRG neurons [55]
and underlie the T-type current in small [13] and medium [38] DRG
neurons in control and under early hyperalgesic PDN conditions.
We have found that SSI of T-type current is right shifted by about
7 mV independently on the type of PDN, resulting in increased chan-
nel availability at the same HMP (Fig. 5Bb). This seems to be a very im-
portant ﬁnding, because even tiny modiﬁcations in SSI voltage
dependence of the T-type channelsmay dramatically modify neuronal
ﬁring [58]. Noteworthily, no SSI shift was reported in the small DRG
neurons in 3–8 days after i.v. STZ injection [13]. However, the shift
was detected in the 2nd week of STZ-diabetes [54]. Thus, the SSI
shift has an onset between the 1st and 2nd weeks of STZ-diabetes
and, according to our results, persists at least up to the 7th week, im-
plicating effects of prolonged hyperglycemia in its development [65].In spite of the similarly increased availability of T-type channels, re-
modeling of these channels is speciﬁc for each PDN type (Fig. 6A). In the
NTCN neurons of hyperalgesic rats functional expression of T-type
channels was not altered compared to control (Fig. 6B,C). In spite of
this, increased availability only was enough to produce a signiﬁcant
upregulation of Cav3.2 T-type channels, as indicated by a signiﬁcant in-
crease in the T-PCD found at HMP≥−95 mV (Figs. 4 and 6). It is nota-
ble that the upregulation became dramatic at resting (−70…−50 mV)
membrane potentials (Fig. 6B). This upregulation of T-type calcium
channels should certainly contribute to the increased excitability of sen-
sory neurons and hyperalgesia [13,19,21,38,66–71]. Thus simulta-
neously upregulated Cav3.2 T-type and TRPV1 channels may play in
concert in expression andmaintenance of thermal hypersensitivity dur-
ing the transition period of PDN.
In the hypoalgesic animalswe have found that functional expression
of T-type channelswas almost twice lower compared to control (Fig. 6B,
C). Comparable downregulation of Cav3.2 alone in healthy rats also
resulted in the development of hypoalgesia [13,19]. Possibly, a certain
level of T-type channel functional expression is necessary for the ther-
mal nociceptive neurons to be ampliﬁers of peripheral pain signals
and a decrease in Cav3.2 expression below this level may result in de-
creased neuronal excitability that may contribute to hypoalgesia
[13,19]. This conclusion is also supported by a greater degree of diabetic
hypoalgesia in Cav3.2−/− compared to control mice [68]. It is interest-
ing to note that in the hypoalgesic animals T-PCD was almost twice
lower compared to hyperalgesic ones in the whole tested range of
HMP (Fig. 6D) indicating that the value of T-PCD is associated with a
particular type of TPS abnormality. Thus, downregulation of Cav3.2 oc-
curring in concert with TRPV1 downregulation may account for the de-
velopment of hypoalgesia during the transition period of PDN.
Wehave not found signiﬁcant differences in functional expression of
T-type channels (Fig. 6C) and TRPV1-channel remodeling (Fig. 3)
between normalgesia and hypoalgesia. However, for HMP≥−70 mV
a signiﬁcant functional upregulation of T-type channels was observed
under conditions of normalgesia, rather than hypoalgesia (Fig. 6B).
This may increase excitability of NTCN neurons of normalgesic rats
and produce a compensatory effect on TRPV1 channel downregulation
leading to normalgesia.
Thus, altered functional expression of T-channels together with the
SSI shift results in either upregulation of T-channels (observed in
hyper- and normalgesia) or downregulation (observed in hypoalgesia).
Several knownmolecularmechanismsmayunderlie the depolarizing
shift in SSI of T-type currents. Themost appealing candidates are alterna-
tive splicing of Cav3.2 isoform [72], modulation by G protein β–γ sub-
units [73] and Rho kinase dependent phosphorylation of Cav3.2 [74].
Many different factors may also contribute to the decreased functional
expression of T-type channels [21] found in the NTCN neurons under
hypo- and normalgesic PDN. However, the physiological relevance of
these mechanisms to the Cav3.2 function in the DRG neurons has not
been studied providing several potential avenues of research aimed at
deciphering the molecular basis of diabetes-induced modulation of
T-type channels.
4.3. Diabetes-induced remodeling of Ca2+ signaling by T-type channels
Remodeling of T-type channels shown in the current study could po-
tentiallymodulate Ca2+ signaling of NTCNneurons. Indeed, [Ca2+]i in re-
sponse to an equal Ca2+ inﬂux via T-type channels is several times higher
in hypo- andnormalgesic rats compared to control andhyperalgesic ones
as indicated by changes in the transient-to-current ratio (Fig. 4F). Since it
has been earlier shown that Ca2+ mobilization from internal stores is
rather decreased under STZ-induced diabetes [63,64], this result indi-
cates that a fast Ca2+ buffering is substantially downregulated under
hypo- and normalgesia.
T-type channels can be a considerable source of Ca2+ entry into the
NTCN neurons of hyperalgesic rats due to a sixfold increase of T-type
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control) found in this study (Fig. 7A). This constant Ca2+ inﬂux should
introduce about 3∗10−18 mol/s of Ca2+ corresponding to 0.1 Hz con-
stant ﬁring (as far as single AP introduces about 2∗10−17 mol of Ca2+
[75]). Since nociceptive neurons are almost silent in terms of AP gener-
ation [76], the T-type window current may substantially contribute to
the overall Ca2+ inﬂux in the NTCN neurons. To pump this additional
Ca2+ inﬂux out, a neuron should hydrolyze ~20 μM/min of ATP that
considerably increases metabolic load on neurons during STZ-diabetes
(up to ~10% of total ATP production rate [77]).
Ca2+ inﬂux introduced by the T-type window current may also in-
ﬂuence a resting [Ca2+]i [47,60–62]. We have estimated this inﬂuence
for NTCN neurons of hyperalgesic rats based on an approach described
in Materials and methods. Following parameters of T-type current
(Fig. 4B,C), related [Ca2+]i transient (Fig. 4D,E) and T-typewindow cur-
rent (Fig. 7A) were used for calculations using Eq. (6) of Materials and
methods: A=50 nM, τtr=5 s, iT=5 pA/pF, τi=20 ms and iwindow=
20 fA/pF. Our estimations demonstrate that T-type window current
may contribute about 50 nM to the resting [Ca2+]i, at least partially un-
derlying its substantial increase observed in the hyperalgesic diabetic
animals (Fig. 7B).
4.4. The functional consequences of T-type channel remodeling
It has been conclusively demonstrated that upregulation of Cav3.2
T-type channels results in a decreased threshold for action potential
generation and burst ﬁring in DRG neurons of control [42] and
hyperalgesic diabetic rats [38]. Thus, a reciprocal remodeling of
T-channels shown in the current study could potentially modulate
peripheral nociceptive input of NTCN neurons, contributing to TPS al-
terations. Our ﬁnding about a manifold increase of T-type window
current in the NTSN neurons of hyperalgesic and normalgesic rats
also seems to be very important due to a previously reported positive
correlation between the T-type window current [47] and cellular ex-
citability [42,78].
Ca2+ signaling by T-type channels may possibly regulate a wide
spectrum of Ca2+-dependent channels expressed in NTCN neurons, in
particular, SK and BK calcium-activated potassium channels. SK and
BK channels are certainly expressed in the IB4 positive small-sized
DRG neurons [79,80] and can substantially modulate their excitability
[81]. Since the coupling of T-type Ca2+ channels to BK and SK channels
has been reported in a number of bursting neurons [82], altered Ca2+
signaling by T-type channels may inﬂuence activity of BK and SK chan-
nels and impact excitability of NTCN neurons under PDN conditions.
Recently presynaptic T-type channels were implicated in regula-
tion of synaptic transmission speciﬁcally between the nociceptive
DRG neurons and dorsal horn neurons of nociceptive lamina I,II
[83,84]. Therefore, T-type channel remodeling observed in this work
may alter synaptic transmission between NTCN and nociceptive dor-
sal horn neurons of rats with PDN in that way contributing to a differ-
ent pain processing at the level of central terminals of NTCN neurons
under different types of PDN.
4.5. Remodeling of TRPV1 and T-type channels during PDN development
All in all, in rats of the same age and duration of diabetes in the tran-
sition period of PDN development we have observed the following: (1)
thermal hyperalgesia is associated with cooperative upregulation of
Cav3.2 channels and TRPV1; (2) thermal normalgesia is associated with
upregulation of Cav3.2 channels and downregulation of TRPV1; (3) ther-
mal hypoalgesia was associated with cooperative downregulation of
Cav3.2 channels and TRPV1.
We suggest the following scenario of TRPV1 and T-type channel
modiﬁcations during diabetes development. At the early stage of diabe-
tes there is a cooperative upregulation of Cav3.2 channels (initially due
to the increased functional expression [13] and later on due to the rightshift in a steady-state channel inactivation [54]) and TRPV1 in the NTCN
neurons resulting in increased peripheral sensitization and develop-
ment of thermal hypersensitivity. Later on a progressive decrease in
functional expression of TRPV1 and Cav3.2 channels leads to the re-
duced functional expression of these channels. However persistent
right shift in a steady-state inactivation of Cav3.2 channel (and conse-
quently increased T-type channel availability) can still maintain
upregulation of T-type channel for a certain period of time. This coun-
teraction of the upregulation of T-type channel and the downregulation
of TRPV1 leads to the normalgesia during the transition period of PDN
development. A further decrease in Cav3.2 functional expression after
8 weeks of diabetes can't be compensated by increased T-type channel
availability. At that stage cooperative downregulation of TRPV1 [15] and
Cav3.2 channel leads to the development of hypoalgesia.
In summary, our results demonstrate that speciﬁc and simultaneous
alterations in functioning of Cav3.2 T-type and TRPV1 channels in the
NTCN neurons may underlie the variety of pain syndromes induced by
type 1 diabetes.Acknowledgments
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